| 1 |
34780066 | DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine-based protocols. | 2022 May |
2 |
| 2 |
35239419 | Survey of US Medical Oncologists' Practices and Beliefs Regarding DPYD Testing Before Fluoropyrimidine Chemotherapy. | 2022 Jun |
1 |
| 3 |
32423482 | DPD status and fluoropyrimidines-based treatment: high activity matters too. | 2020 May 18 |
2 |
| 4 |
32619063 | Impact of DPYD, DPYS, and UPB1 gene variations on severe drug-related toxicity in patients with cancer. | 2020 Sep |
1 |
| 5 |
32899374 | A Genotyping/Phenotyping Approach with Careful Clinical Monitoring to Manage the Fluoropyrimidines-Based Therapy: Clinical Cases and Systematic Review of the Literature. | 2020 Sep 3 |
3 |
| 6 |
30361102 | Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers. | 2018 Nov |
2 |
| 7 |
21344302 | Final results of a prematurely discontinued Phase 1/2 study of eniluracil with escalating doses of 5-fluorouracil administered orally in patients with advanced hepatocellular carcinoma. | 2011 Oct |
1 |
| 8 |
19288105 | Lack of large intragenic rearrangements in dihydropyrimidine dehydrogenase (DPYD) gene in fluoropyrimidine-treated patients with high-grade toxicity. | 2009 Aug |
1 |